The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.
 
Xavier Leleu
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; GlaxoSmithKline; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Merck; Novartis; Oncopeptides; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Merck; Novartis; Oncopeptides; Roche; Takeda
Travel, Accommodations, Expenses - Takeda
 
Maria-Victoria Mateos
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Regeneron; Roche/Genentech; Takeda
 
Sundar Jagannath
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Janssen; Merck
 
Sosana Delimpasi
Consulting or Advisory Role - Amgen; Amgen; Janssen; Takeda
Speakers' Bureau - Amgen; Janssen; Takeda
 
Maryana Simonova
No Relationships to Disclose
 
Ivan Spicka
Honoraria - Amgen; Celgene; Janssen-Cilag; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag
 
Luděk Pour
No Relationships to Disclose
 
Iryna Kriachok
Consulting or Advisory Role - Janssen; Takeda
Research Funding - Abbvie; Acerta Pharma; Bayer; Debiopharm Group; Janssen; Karyopharm Therapeutics; MSD
Expert Testimony - Janssen; Takeda
Travel, Accommodations, Expenses - Abbvie; MSD; Roche; Takeda
 
Maria Gavriatopoulou
Honoraria - Amgen; Celgene; Janssen; Takeda
Consulting or Advisory Role - Amgen; Karyopharm Therapeutics
Research Funding - Novartis
Travel, Accommodations, Expenses - Genesis Pharma; Janssen; Takeda
 
Meletios A. Dimopoulos
Honoraria - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Takeda
 
Halyna Pylypenko
No Relationships to Disclose
 
Holger W. Auner
Consulting or Advisory Role - Karyopharm Therapeutics; Takeda
Speakers' Bureau - Janssen
Research Funding - Amgen
 
Vadim Doronin
No Relationships to Disclose
 
Benjamin Reuben
No Relationships to Disclose
 
Christopher P. Venner
Honoraria - Amgen; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
 
Mamta Garg
Travel, Accommodations, Expenses - Takeda
 
Andrew DeCastro
Employment - Karyopharm Therapeutics
 
Jatin J. Shah
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sebastian Grosicki
No Relationships to Disclose
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Oncopeptides (Inst); Takeda (Inst)